Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Imipenem

FDA-approved product (powder, intravenous).

Registered studies
50+
Lab records
505
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Imipenem
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Endocarditis
  • Infection
  • Pneumonia
  • Sepsis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbapenems
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DH51

Repurposing investigation

Imipenem is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli97.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae96.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 44 of 77 lab records
  • E. coli: measured active in 86 of 94 lab records
  • K. pneumoniae: measured active in 247 of 334 lab records
Open Imipenem in ChEMBL Registered studies below
Show the latest 150 of 505 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Imipenem with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

    NCT02452047 · start 2015-08-21

    Registered record
    Registry ID
    NCT02452047
    Conditions
    Bacterial Infections
    Interventions
    Imipenem+Cilastatin/Relebactam; Colistimethate sodium (CMS); Imipenem+Cilastatin; Placebo to CMS
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-08-21
    Completion
    2017-09-18
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionImipenem+Cilastatin/Relebactam; Colistimethate sodium (CMS); Imipenem+Cilastatin; Placebo to CMS
    PhasePhase 3
    Registry statusCompleted

  • A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections

    NCT02321800 · start 2015-02-05

    Registered record
    Registry ID
    NCT02321800
    Conditions
    Urinary Tract Infections
    Interventions
    Cefiderocol; Imipenem/cilastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-02-05
    Completion
    2016-08-16
    Enrolment
    452

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionCefiderocol; Imipenem/cilastatin
    PhasePhase 2
    Registry statusCompleted

  • Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin

    NCT02616354 · start 2015-01

    Registered record
    Registry ID
    NCT02616354
    Conditions
    Sepsis
    Interventions
    Imipenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2015-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionImipenem
    PhasePhase 4
    Registry statusUnknown

  • Imipenem Prophylaxis in Patients With Acute Pancreatitis

    NCT02897206 · start 2014-10

    Registered record
    Registry ID
    NCT02897206
    Conditions
    Acute Pancreatitis
    Interventions
    Imipenem; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-10
    Completion
    2016-12
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Pancreatitis
    InterventionImipenem; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock

    NCT02191475 · start 2014-05

    Registered record
    Registry ID
    NCT02191475
    Conditions
    Abdominal Infection
    Interventions
    glycopeptide plus carbapenem; Haizheng Li Xing ® plus tazocin ®
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2014-05
    Completion
    2017-05
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAbdominal Infection
    Interventionglycopeptide plus carbapenem; Haizheng Li Xing ® plus tazocin ®
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Pharmacokinetics of Imipenem During Ex Vivo Lung Perfusion (EVLP)

    NCT02670239 · start 2014-05

    Registered record
    Registry ID
    NCT02670239
    Conditions
    Lung Transplantation
    Interventions
    normothermic ex vivo lung perfusion
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2014-05
    Completion
    Not recorded
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Transplantation
    Interventionnormothermic ex vivo lung perfusion
    PhaseNot recorded
    Registry statusUnknown

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated

  • Effect of Aerosolised Colistin in Ventilator Associated Pneumonia

    NCT02683603 · start 2013-04

    Registered record
    Registry ID
    NCT02683603
    Conditions
    Pneumonia, Ventilator-Associated
    Interventions
    AS colistin and "imipenem"; IV colistin " and "imipenem" .; AS colimycin (colistin); IV colimycin (colistin); AS colistin and imipenem; IV colistin and imipenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-04
    Completion
    2015-04
    Enrolment
    133

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia, Ventilator-Associated
    InterventionAS colistin and "imipenem"; IV colistin " and "imipenem" .; AS colimycin (colistin); IV colimycin (colistin) +2 more
    PhasePhase 4
    Registry statusCompleted

  • A Comparative Study of ID Fellow-based VS. Pharmacist-based Antibiotic Pre-authorization

    NCT01797133 · start 2013-02

    Registered record
    Registry ID
    NCT01797133
    Conditions
    All Hospitalzied Patients; No Specific Conditions Requires
    Interventions
    ID fellow-based antibiotic pre-authorization; Pharmacist-based antibiotic pre-authorization
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-02
    Completion
    2013-12
    Enrolment
    984

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAll Hospitalzied Patients; No Specific Conditions Requires
    InterventionID fellow-based antibiotic pre-authorization; Pharmacist-based antibiotic pre-authorization
    PhaseNot applicable
    Registry statusCompleted

  • Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia

    NCT01714570 · start 2012-11

    Registered record
    Registry ID
    NCT01714570
    Conditions
    Febrile; Neutropenia; Hematopoietic Stem Cell Transplantation
    Interventions
    Piperacillin-tazobactam combination product; Imipenem
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-04
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile; Neutropenia; Hematopoietic Stem Cell Transplantation
    InterventionPiperacillin-tazobactam combination product; Imipenem
    PhaseNot applicable
    Registry statusCompleted

  • Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments

    NCT01703299 · start 2012-10

    Registered record
    Registry ID
    NCT01703299
    Conditions
    Carbapenem-induced Resistance
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-10
    Completion
    2014-03
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-induced Resistance
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Antibiotic Prophylaxis for Transrectal Prostate Biopsy

    NCT01659866 · start 2012-08

    Registered record
    Registry ID
    NCT01659866
    Conditions
    Infection
    Interventions
    Ciprofloxacin; trimethoprim-sulfamethoxazole; cefuroxime; ceftriaxone; gentamicin; amikacin; aztreonam; imipenem; ceftriaxone; gentamicin; amikacin; aztreonam; imipenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-08
    Completion
    2016-08
    Enrolment
    563

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    InterventionCiprofloxacin; trimethoprim-sulfamethoxazole; cefuroxime; ceftriaxone +9 more
    PhasePhase 4
    Registry statusCompleted

  • Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)

    NCT01505634 · start 2012-05-16

    Registered record
    Registry ID
    NCT01505634
    Conditions
    Urinary Tract Infections; Pyelonephritis
    Interventions
    Relebactam 250 mg; Relebactam 125 mg; imipenem/cilastatin 500 mg; Placebo to relebactam; Ciprofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-05-16
    Completion
    2015-07-28
    Enrolment
    302

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections; Pyelonephritis
    InterventionRelebactam 250 mg; Relebactam 125 mg; imipenem/cilastatin 500 mg; Placebo to relebactam +1 more
    PhasePhase 2
    Registry statusCompleted

  • A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)

    NCT01275170 · start 2011-01-28

    Registered record
    Registry ID
    NCT01275170
    Conditions
    Infectious Disease
    Interventions
    MK-7655; Imipenem + Cilastatin; Caffeine; Midazolam; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-01-28
    Completion
    2012-03-05
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfectious Disease
    InterventionMK-7655; Imipenem + Cilastatin; Caffeine; Midazolam +1 more
    PhasePhase 1
    Registry statusCompleted

  • Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections

    NCT00690378 · start 2008-11

    Registered record
    Registry ID
    NCT00690378
    Conditions
    Complicated Urinary Tract Infection
    Interventions
    NXL104/ceftazidime; Imipenem/Cilastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-11
    Completion
    2010-07
    Enrolment
    137

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infection
    InterventionNXL104/ceftazidime; Imipenem/Cilastatin
    PhasePhase 2
    Registry statusCompleted